Trillium Therapeutics Inc. (NASDAQ: TRIL) is 701.94% higher on its value in year-to-date trading and has touched a low of $0.24 and a high of $9.66 in the current 52-week trading range. The TRIL stock was last observed hovering at around $7.39 in the last trading session, with the day’s gains setting it 0.87% off its average median price target of $11.00 for the next 12 months. It is also 44.93% off the consensus price target high of $15.00 offered by 6 analysts, but current levels are -3.25% lower than the price target low of $8.00 for the same period.
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Currently trading at $8.26, the stock is 10.16% and 7.54% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.85 million and changing 11.77% at the moment leaves the stock 96.73% off its SMA200. TRIL registered 2443.10% gain for a year compared to 6-month gain of 114.55%. The firm has a 50-day simple moving average (SMA 50) of $7.73 and a 200-day simple moving average (SMA200) of $5.73.
The stock witnessed a 14.25% loss in the last 1 month and extending the period to 3 months gives it a 37.67%, and is 23.65% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.38% over the week and 8.13% over the month.
Distance from 52-week low is 3334.51% and -14.49% from its 52-week high.
Trillium Therapeutics Inc. (TRIL) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Trillium Therapeutics Inc. (TRIL) is a “Buy”. 6 analysts offering their recommendations for the stock have an average rating of 1.50, where 1 rate it as a Hold and 0 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Trillium Therapeutics Inc. is expected to release its quarterly report on 08/07/2020 and quarterly earnings per share for the current quarter are estimated at -$0.9.The EPS is expected to shrink by -26.90% this year.
Trillium Therapeutics Inc. (TRIL) Top Institutional Holders
38 institutions hold shares in Trillium Therapeutics Inc. (TRIL), with 55.07k shares held by insiders accounting for 0.07% while institutional investors hold 32.74% of the company’s shares. The shares outstanding are 83.44M, and float is at 59.89M with Short Float at 4.16%. Institutions hold 32.72% of the Float.